Investor's Business Daily on MSN
Roivant Sciences catapults on a 'dream scenario' for its blockbuster hopeful
Roivant Sciences unveiled "exceptional" results Friday for its skin disease treatment, sending the biotech stock flying.
Merck & Co. Inc.’s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck MRK said a trial of the drug, given ...
Sanofi and Regeneron Pharmaceuticals drug Dupixent has won FDA approval for chronic spontaneous urticaria, introducing a new approach to the treatment of this inflammatory skin disorder. It’s the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results